Q1 2022 Alligator Bioscience AB Earnings Call Transcript
¸ -
Thank you and welcome to this interim report call from Alligator Bioscience. My name is Søren Bregenholt, the CEO of the Alligator Bioscience. And with me today, I have our Chief Financial Officer, Marie Svensson. Before we get into the actual call, if we could have the disclaimer, I want to remind you that during this call there will be forward-looking statements, both on the financial performance and the actual project performance of the company.
If we go to slide number 3, I just wanted to highlight some of the priorities that we -- and some of the milestones that Alligator achieved during 2021, allowing us to go into 2022 in a strong position. First of all, we initiated Phase II clinical development with our lead asset, Mitazalimab, in first-line pancreatic cancer patients in combination Folfirinox chemotherapy; Phase I assets, 1017, we reported positive biomarker data, and the intention to move -- and safety data and the intention to move forward to Phase II.
We presented several collaborations during the year
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
